2型糖尿病市場規模、佔有率和成長分析：按藥物類別、給藥途徑、人口統計、分銷管道和地區分類－2026-2033年產業預測

2024 年全球 2 型糖尿病市場價值為 345 億美元，預計到 2025 年將成長至 371.6 億美元，到 2033 年將成長至 672.6 億美元，在預測期（2026-2033 年）內複合年成長率為 7.7%。

全球第2型糖尿病市場受該疾病盛行率不斷上升的驅動，導致對有效治療方法的需求日益成長。製藥公司正透過開發創新藥物來推動市場成長，例如鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑和類升糖素肽-1 (GLP-1) 受體促效劑，這些藥物在提供更佳治療方案的同時，還能減少副作用。然而，患者對這些新治療方法的認知度較低，可能會阻礙其廣泛應用。為了滿足日益成長的醫療保健需求，該行業面臨著巨大的擴張機遇，尤其是在那些能夠以可負擔的價格提供先進治療方案的領域。此外，包括行動醫療應用程式和雲端解決方案在內的技術進步，正在提高治療的可及性和有效性，從而進一步促進這一關鍵醫療保健領域的市場成長。

全球第2型糖尿病市場成長要素

全球第2型糖尿病市場的主要促進因素之一是全球人口中肥胖和久坐生活方式的日益普遍。隨著肥胖率的上升，第2型糖尿病的發生率也在激增，從而推動了對有效治療方法和管理方案的需求。此外，人們對該疾病及其併發症的認知不斷提高，以及技術和藥物研發的進步，都在推動糖尿病護理領域的創新。隨著醫療保健系統努力應對日益沉重的糖尿病負擔，對研發的投資以及新藥和醫療設備的推出，進一步促進了市場成長。

全球第2型糖尿病市場面臨的限制因素

全球第2型糖尿病市場的主要限制因素之一是文明病的日益普遍，這往往使糖尿病的治療和依從性更加困難。隨著越來越多的人患有肥胖症、心血管疾病和METABOLIC INC.症候群，人們對綜合健康管理的日益關注可能會分散對糖尿病特異性治療方法的興趣和資源。此外，糖尿病藥物和醫療設備的高昂成本會對醫療保健預算造成壓力，可能導致治療中斷和疾病管理不善。這些因素綜合起來可能會限制患者獲得必要治療的機會，進而阻礙市場成長，最終影響第二型糖尿病患者的治療效果。

2型糖尿病市場的全球趨勢

全球第2型糖尿病市場正經歷著向遠端監測和數位化健康解決方案的顯著轉變，這反映出疾病管理中對科技的依賴性日益增強。創新的穿戴式裝置和行動應用程式使患者能夠持續監測血糖值，並與醫療專業人員即時共用數據。這種積極主動的方法有助於提高病患的用藥依從性，追蹤整體健康狀況，進而提升醫療品質和病患參與度。因此，這些技術的應用預計將帶來更好的健康結果，同時降低醫療成本，顯示將數位化健康融入第2型糖尿病管理的趨勢十分強勁。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球第 2 型糖尿病市場規模：依藥物類別分類

• 胰島素
• DPP-4抑制劑
• GLP-1受體促效劑
• SGLT2抑制劑
• 其他

全球第2型糖尿病市場規模：依給藥途徑分類

• 口服
• 皮下
• 吸入

全球第2型糖尿病市場規模：依人口統計群體分類

• 年齡層
  • 18-39歲
  • 40-49歲
  • 50-59歲
  • 60歲或以上
• 性別
  • 男性
  • 女士

全球 2 型糖尿病市場規模：按分銷管道分類

• 網路藥房
• 醫院藥房
• 零售藥房

全球第2型糖尿病市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Johnson & Johnson
• Abbott Laboratories
• Medtronic plc
• Dexcom, Inc.
• Insulet Corporation
• Sun Pharmaceutical Industries Limited
• Amgen Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company

結論與建議

Global Type 2 Diabetes Market size was valued at USD 34.5 Billion in 2024 and is poised to grow from USD 37.16 Billion in 2025 to USD 67.26 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global type 2 diabetes market is propelled by the increasing prevalence of the condition, leading to heightened demand for effective treatment options. Pharmaceutical companies are driving market growth through the development of innovative drugs, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, which offer better management options with reduced side effects. However, the lack of awareness regarding these new treatments among patients may hinder their widespread acceptance. In response to rising medical needs, the industry faces significant opportunities for expansion, particularly in providing affordable and advanced treatment solutions. Additionally, technological advancements, including mobile health applications and cloud-based solutions, are enhancing accessibility and effectiveness, further contributing to market growth in this critical healthcare segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Type 2 Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Type 2 Diabetes Market Segments Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Demographics, Distribution Channel and region. Based on Drug Class, the market is segmented into Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Others. Based on Route of Administration, the market is segmented into Oral, Subcutaneous and Inhalation. Based on Demographics, the market is segmented into Age Group and Gender. Based on Distribution Channel, the market is segmented into Online Pharmacies, Hospital Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Type 2 Diabetes Market

One of the key market drivers for the global type 2 diabetes market is the increasing prevalence of obesity and sedentary lifestyles among populations worldwide. As obesity rates rise, the incidence of type 2 diabetes has escalated, leading to higher demand for effective treatment options and management solutions. Additionally, heightened awareness of the disease and its complications, coupled with advancements in technology and drug development, is driving innovation in diabetes care. As healthcare systems strive to manage the growing burden of diabetes, investment in research and the introduction of new medications and devices are further propelling market growth.

Restraints in the Global Type 2 Diabetes Market

One key market restraint for the global type 2 diabetes market is the increasing prevalence of lifestyle-related diseases, which often complicate diabetes management and treatment adherence. As more individuals suffer from obesity, cardiovascular issues, and metabolic syndrome, the focus on holistic health management may divert attention and resources from diabetes-specific therapies. Additionally, the high costs associated with diabetes medications and devices can strain healthcare budgets, leading to treatment discontinuation and poor disease management. These factors combined could hinder growth by limiting access to necessary therapies and ultimately affecting patient outcomes in managing type 2 diabetes.

Market Trends of the Global Type 2 Diabetes Market

The Global Type 2 Diabetes market is experiencing a significant shift towards remote monitoring and digital health solutions, reflecting an increasing reliance on technology for disease management. Innovative wearable devices and mobile applications empower patients to continuously monitor their glucose levels and share real-time data with healthcare providers. This proactive approach facilitates improved medication adherence and overall health tracking, enhancing care quality and patient engagement. As a result, the utilization of these technologies is projected to drive better health outcomes while simultaneously lowering healthcare costs, indicating a robust trend towards integrating digital health in the management of Type 2 diabetes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Type 2 Diabetes Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Insulin
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors
• Others

Global Type 2 Diabetes Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Subcutaneous
• Inhalation

Global Type 2 Diabetes Market Size by Demographics & CAGR (2026-2033)

• Market Overview
• Age Group
  • 18-39
  • 40-49
  • 50-59
  • Above 60
• Gender
  • Male
  • Female

Global Type 2 Diabetes Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Global Type 2 Diabetes Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Demographics, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Demographics, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Demographics, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Demographics, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Demographics, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations